Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia.
Jack GhannamLaura W DillonChristopher S HouriganPublished in: British journal of haematology (2019)
Acute myeloid leukaemia (AML) is a blood cancer characterized by acquired genetic mutations. There is great interest in accurately establishing measurable residual disease (MRD) burden in AML patients in remission after treatment but at risk of relapse. However, inter- and intrapatient genetic diversity means that, unlike in the chronic myeloid and acute promyelocytic leukaemias, no single genetic abnormality is pathognomonic for all cases of AML MRD. Next-generation sequencing offers the opportunity to test broadly and deeply for potential genetic evidence of residual AML, and while not currently accepted for such use clinically, is likely to be increasingly used for AML MRD testing in the future.
Keyphrases
- acute myeloid leukemia
- liver failure
- copy number
- allogeneic hematopoietic stem cell transplantation
- respiratory failure
- genetic diversity
- drug induced
- genome wide
- aortic dissection
- bone marrow
- dendritic cells
- ejection fraction
- end stage renal disease
- prognostic factors
- papillary thyroid
- circulating tumor
- intensive care unit
- systemic lupus erythematosus
- squamous cell
- acute lymphoblastic leukemia
- extracorporeal membrane oxygenation
- patient reported outcomes
- rheumatoid arthritis
- disease activity
- ulcerative colitis
- cell free